Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Actinomycin D

Related Products

Hot Products

Name

Actinomycin D

EINECS 200-063-6
CAS No. 50-76-0 Density 1.42 g/cm3
PSA 359.98000 LogP 2.37360
Solubility soluble in water Melting Point 251-253 °C
Formula C62H86N12O16 Boiling Point 1386 °C at 760 mmHg
Molecular Weight 1255.44 Flash Point 792.1 °C
Transport Information UN 3462 6.1/PG 2 Appearance red crystalline powder
Safety 53-36/37/39-45-1-28-22 Risk Codes 61-40-45-26/27/28
Molecular Structure Molecular Structure of 50-76-0 (Actinomycin D) Hazard Symbols VeryT+
Synonyms

3H-Phenoxazine-1,9-dicarboxamide,2-amino-N,N'-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-(7CI);Actinomycin C1 (6CI);1H-Pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecine, cyclic peptidederiv.;Actactinomycin A IV;Actinomycin 7;Actinomycin AIV;Actinomycin I1;Actinomycin IV;Actinomycin X1;Actinomycindioic D acid, dilactone;Chounghwamycin B;Cosmegen;Dactinomycin;Dilactone actinomycin D acid;Lyovac cosmegen;NCI C04682;Oncostatin K;Stereoisomer ofN,N'-[(2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis[carbonylimino[2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl]imino[2-(1-methylethyl)-1-oxo-2,1-ethanediyl]-1,2-pyrrolidinediylcarbonyl(methylimino)(1-oxo-2,1-ethanediyl)]]bis[N-methyl-L-valine]di-x-lactone;

Article Data 12

Actinomycin D Consensus Reports

ARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 (1987),p. 80.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; NCI Carcinogenesis Studies (ipr); No Evidence: mouse RRCRBU    Recent Results in Cancer Research. 52 (1975),1.

Actinomycin D Specification

The Actinomycin D with the cas number 50-76-0. It is also called 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide name by IUPAC. It seems like bright red rhomboid prisms or red powder. It belongs to the flollowing product categories: (1)Antibiotics; (2)Antibiotic Explorer; (3)Intermediates & Fine Chemicals; (4)Peptides; (5)Pharmaceuticals; (6)Caspases/Apoptosis. Actinomycin D is stable, but light sensitive, especially in dilute solution. And it is incompatible with strong acids, strong bases, strong oxidizing agents. Besides, it is quite combustible. It is should be stored at 2-8°C.

Properties of Actinomycin D are: (1)ACD/LogP: -0.33 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): -2.83 ; (4)ACD/LogD (pH 7.4): -2.83 ; (5)ACD/BCF (pH 5.5): 1 ; (6)ACD/BCF (pH 7.4): 1 ; (7)ACD/KOC (pH 5.5): 1 ; (8)ACD/KOC (pH 7.4): 1 ; (9)#H bond acceptors: 3 ; (10)#H bond donors: 3 ; (11)#Freely Rotating Bonds: 2 ; (12)Polar Surface Area: 29.54Å2 ; (13)Index of Refraction: 1.464 ; (14)Molar Refractivity: 25.64 cm3 ; (15)Molar Volume: 92.9 cm3 ; (16)Polarizability: 10.16 ×10-24cm3 ; (17)Surface Tension: 42.4 dyne/cm ; (18)Density: 1.109 g/cm3 ; (19)Flash Point: 77.4 °C ; (20)Enthalpy of Vaporization: 48.56 kJ/mol ; (21)Boiling Point: 204.4 °C at 760 mmHg ; (22)Vapour Pressure: 0.108 mmHg at 25°C

Uses of Actinomycin D: Actinomycin D is mainly used as an investigative tool in cell biology to inhibit transcription. Besides, Actinomycin D is one chemotherapy drug which has a long history, and has been used in therapy for many years. In additon, it is also used intravenously in treatment of a variety of cancers including gestational trophoblastic neoplasia, Wilms' tumor and rhabdomyosarcoma and so on.

When you are using Actinomycin D, please be cautious about it as the following: It is quite irritating to eyes, respiratory system and skin. When you are using this chemical, please wear suitable gloves and eye/face protection to avoid contact with skin and eyes. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Besides, it is very toxic by inhalation, in contact with skin and if swallowed. For instance, it may cause harm to the unborn child and may cause cancer, tough with limited evidence of a carcinogenic effect. Hence, in order not to breathe dust, you would better keep it locked up, and avoid exposure - obtain special instructions before use. After contact with skin, wash immediately with plenty of soap-suds.

You can still convert the following datas into molecular structure :
1.SMILES:O=C(O)C(N)(C)C
2.InChI:InChI=1/C4H9NO2/c1-4(2,5)3(6)7/h5H2,1-2H3,(H,6,7)

Toxic information of Actinomycin D can be showed as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
bird - wild LD50 oral 1mg/kg (1mg/kg)   Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
cat LDLo intraperitoneal 75ug/kg (0.075mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Antibiotiki. Vol. 16, Pg. 443, 1971.
dog LDLo intravenous 160ug/kg (0.16mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

BLOOD: LEUKOPENIA
National Technical Information Service. Vol. PB225-594,
guinea pig LD50 unreported 330ug/kg (0.33mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
hamster LD50 unreported 600ug/kg (0.6mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
human TDLo intravenous 40ug/kg/4D-I (0.04mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" New England Journal of Medicine. Vol. 281, Pg. 1094, 1969.
mouse LD50 intraperitoneal 750ug/kg (0.75mg/kg) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE

IMMUNOLOGICAL INCLUDING ALLERGIC: DECREASED IMMUNE RESPONSE
Cancer Treatment Reports. Vol. 61, Pg. 103, 1977.
mouse LD50 intravenous 1025ug/kg (1.025mg/kg)   Antibiotiki. Vol. 16, Pg. 443, 1971.
mouse LD50 oral 13mg/kg (13mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BLOOD: OTHER CHANGES
Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
mouse LD50 subcutaneous 500ug/kg (0.5mg/kg)   "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978Vol. 2, Pg. 1268, 1978.
mouse LDLo intratracheal 1mg/kg (1mg/kg)   Toxicology Letters. Vol. 30, Pg. 63, 1986.
rabbit LD50 unreported 150ug/kg (0.15mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
rat LD50 intraperitoneal 100ug/kg (0.1mg/kg)   Acta Obstetrica et Gynaecologica Japonica, English Edition. Vol. 23, Pg. 219, 1976.
rat LD50 intravenous 460ug/kg (0.46mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BLOOD: OTHER CHANGES
Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
rat LD50 oral 7200ug/kg (7.2mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BLOOD: OTHER CHANGES
Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
rat LD50 subcutaneous 800ug/kg (0.8mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BLOOD: OTHER CHANGES
Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50-76-0